Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) Operating Expenses (2016 - 2025)

Historic Operating Expenses for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to $21.7 million.

  • CytomX Therapeutics' Operating Expenses fell 2588.59% to $21.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.4 million, marking a year-over-year decrease of 2462.07%. This contributed to the annual value of $113.1 million for FY2024, which is 502.33% up from last year.
  • Latest data reveals that CytomX Therapeutics reported Operating Expenses of $21.7 million as of Q3 2025, which was down 2588.59% from $19.9 million recorded in Q2 2025.
  • In the past 5 years, CytomX Therapeutics' Operating Expenses ranged from a high of $46.0 million in Q4 2021 and a low of $19.9 million during Q2 2025
  • In the last 5 years, CytomX Therapeutics' Operating Expenses had a median value of $29.6 million in 2022 and averaged $31.5 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first skyrocketed by 4777.54% in 2021, then plummeted by 4306.73% in 2023.
  • Over the past 5 years, CytomX Therapeutics' Operating Expenses (Quarter) stood at $46.0 million in 2021, then plummeted by 35.63% to $29.6 million in 2022, then dropped by 8.16% to $27.2 million in 2023, then fell by 24.98% to $20.4 million in 2024, then grew by 6.45% to $21.7 million in 2025.
  • Its Operating Expenses was $21.7 million in Q3 2025, compared to $19.9 million in Q2 2025 and $28.3 million in Q1 2025.